Target | Drug (manufacturer) | Drug type | Protocol and tumor types | Therapeutic combinations |
TIGIT | BMS-986207 (Bristol Myers Squibb) | TIGIT blocking human IgG1 mAb | Phase I/II in patients with multiple myeloma with relapse | BMS-986207 or Elotuzumab (anti-SLAMF7) or Relatimab (anti-LAG-3) +Potomalidimide +Dexamethasone |
BGB-A1217 (BeiGene) | TIGIT blocking humanized IgG1 mAb | Phase I/Ib in patients with metastatic solid tumors | BGB-A1217 +Tislelizumab (anti-PD-1) | |
Tiragolumab, MTIG7192A (Genentech) | TIGIT blocking human IgG1 mAb | Phase II in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer | Tiragolumab or placebo +Atezolizumab (anti-PD-L1) | |
Tiragolumab, MTIG7192A (Genentech) | TIGIT blocking human IgG1 mAb | Phase III in patients with untreated extensive-stage small lung cell cancer | Tiragolumab or placebo +Atezolizumab (anti-PD-L1) +Etoposide +Carboplatin | |
Tiragolumab, MTIG7192A (Genentech) | TIGIT blocking human IgG1 mAb | Phase III in patients with untreated locally advanced, unresectable, or metastatic PD-L1-selected non-small cell lung cancer | Tiragolumab or placebo +Atezolizumab (anti-PD-L1) | |
Tiragolumab, MTIG7192A (Genentech) | TIGIT blocking human IgG1 mAb | Phase Ib/II in patients with locally advanced unresectable or metastatic gastro-esophageal junction cancer or esophageal cancer | Tiragolumab +Atezolizumab (anti-PD-L1) or Tiragolumab +Atezolizumab (anti-PD-L1) +Cisplatin +5-Fluorouracil or combinations without Tiragolumab | |
AB154 (Arcus Biosciences) | TIGIT blocking humanized IgG1 mAb | Phase I in patients with advanced solid malignancies | AB154 +Zimberelimab (anti-PD-1) or Zimberelimab alone | |
AB154 (Arcus Biosciences) | TIGIT blocking humanized IgG1 mAb | Phase II in patients with PD-L1 positive, locally advanced or metastatic non-small cell lung cancer | AB154 +Zimberelimab (anti-PD-1) AB154 +Zimberelimab +AB928 (anti-A2a/bR antagonist) or Zimberelimab alone | |
ASP8374 (Astella Pharma Global Development) | TIGIT blocking human IgG4 mAb | Phase Ib in patients with advanced tumors | ASP8374 +Pembrolizumab (anti-PD-1) | |
MK-7684 (Merck Sharp & Dohme) | TIGIT blocking humanized IgG1 mAb | Phase I/II in patients with melanoma | MK-7684 +Pembrolizumab (anti-PD-1) or Pembrolizumab alone | |
MK-7684 (Merck Sharp & Dohme) | TIGIT blocking humanized IgG1 mAb | Phase I/II in patients with PD-1 refractory melanoma | MK-7684 or Lenvatinib +Pembrolizumab (anti-PD-1) +MK-1308 (anti-CTLA-4) | |
CD112R | COM701 (Compugen) | CD112R/PVRIG inhibitor | Phase I in patients with advanced solid tumors | COM701 +Nivolumab (anti-PD-1) or COM701 alone |
CD226 | LY3435151 (Eli Lilly and Company) | CD226 agonist | Phase Ia/Ib in patients with advanced solid tumors | LY3435151 +Pembrolizumab (anti-PD-1) or LY3435151 alone |
Antibodies targeting TIGIT and drugs targeting CD112R or CD226 found on ClinicalTrials.gov (as of April 2020) that are currently active in clinical trials for the indicated tumor types, with the therapeutic combination listed.
IgG, immunoglobulin; mAb, monoclonal antibody; PD-1, programmed cell death receptor 1.